Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells

Cancer Gene Therapy volume 19, pages 271–281 (2012)Cite this article

Subjects

Abstract

Aurora A has multiple key functions in tumor initiation and progression and is overexpressed in many cancers. Several ongoing clinical trials are assessing the unique therapeutic potential of Aurora-based targeted therapy, but several severe adverse events such as hematopoietic toxicity have been observed in the early-phase clinical trials because Aurora A is also involved in normal cells proliferation process. The strategy to develop tumor-specific inhibition of this target may be an alteration for the treatment of Aurora A overexpression tumors. In this study, we developed a novel tumor-specific RNA interference adenovirus system targeting Aurora A by using stathmin promoter and investigated the effects of it on the proliferation, apoptosis and chemotherapy sensitivity in human breast carcinoma cells both in vitro and in vivo. The results showed that treatment of human breast carcinoma cells (SK-BR-3 and MDA-MB-231) by Aurora A short hairpin RNA (shRNA) driven by stathmin gene promoter not only inhibited the cells proliferation, but also enhanced the chemosensitivity to paclitaxel via downregulation of Aurora A mRNA and protein expression, which further decreased the phosphatidylinositol 3 kinase/Akt and p-BRCA1 protein expression. Furthermore, there were no obvious phenotypes changes observed in normally differentiated epithelial cells of MCF210. Therefore, stathmin promoter-driving Aurora A shRNA adenoviral system may have potential use, with targeted tumor gene silencing effect and as adjuvant tumor-specific therapy method, in the treatment of human breast carcinomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007; 18: 215–225.

    Article  CAS  Google Scholar 

  2. Biganzoli L, Minisini A, Aapro M, Di Leo A . Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol 2004; 16: 37–41.

    Article  Google Scholar 

  3. Glover DM, Leibowitz MH, McLean DA, Parry H . Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 1995; 81: 95–105.

    Article  CAS  Google Scholar 

  4. Andrews PD, Knatko E, Moore WJ, Swedlow JR . Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 2003; 15: 672–683.

    Article  CAS  Google Scholar 

  5. Liu XS, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J et al. Akt inhibitor A-443654 interferes with mitotic progression by regulating Aurora A kinase expression. Neoplasia 2008; 10: 828–837.

    Article  CAS  Google Scholar 

  6. Marumoto T, Zhang D, Saya H . Aurora-A—a guardian of poles. Nat Rev Cancer 2005; 5: 42–50.

    Article  CAS  Google Scholar 

  7. Ruchaud S, Carmena M, Earnshaw WC . Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8: 798–812.

    Article  CAS  Google Scholar 

  8. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 2007; 67: 10436–10444.

    Article  CAS  Google Scholar 

  9. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP et al. Aurora-A is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010; 70: 4655–4665.

    Article  CAS  Google Scholar 

  10. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T et al. Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression. Blood 2009; 114: 2699–2708.

    Article  CAS  Google Scholar 

  11. Dar A, Laura W, Goff L, Majid S, Berlin J, El-Rifai W . Aurora kinases’ inhibitors—rising stars in cancer therapeutics? Mol Cancer Ther 2010; 9: 268.

    Article  CAS  Google Scholar 

  12. Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G et al. The role of Aurora-A inhibitors in cancer therapy. Annals Oncol 2007; 18: 47–52.

    Article  Google Scholar 

  13. Lin F, Long M, Yan L, Gao P, Wang R, Zhang Y et al. Downregulation of stathmin expression is mediated directly by Egr1 and associated with p53 activity in lung cancer cell line A549. Cell Signal 2010; 22: 166–173.

    Article  CAS  Google Scholar 

  14. Tong T, Zhong Y, Kong J, Dong L, Song Y, Fu M et al. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 2004; 10: 7304–7310.

    Article  CAS  Google Scholar 

  15. Kloog I, Stevens RG, Haim A, Portnov BA . Nighttime light level codistributes with breast cancer incidence worldwide. Cancer Causes Control 2010; 21: 2059–2068.

    Article  Google Scholar 

  16. Pines J, Rieder CL . Re-staging mitosis: a contemporary view of mitotic progression. Nat Cell Biol 2001; 3: 3–6.

    Article  Google Scholar 

  17. Schatten H . The mammalian centrosome and its functional significance. Histochem Cell Biol 2008; 129: 667–686.

    Article  CAS  Google Scholar 

  18. Morris PG, Fornier MN . Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14: 7167–7172.

    Article  CAS  Google Scholar 

  19. Zhou J, Giannakakou P . Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005; 5: 65–71.

    Article  CAS  Google Scholar 

  20. Jiang Y, Zhang Y, Lees E, Seghezzi W . AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer. Oncogene 2003; 22: 8293–8301.

    Article  CAS  Google Scholar 

  21. Jantscher F, Pirker C, Mayer CE, Berger W, Sutterluety H . Overexpression of Aurora-A in primary cells interferes with S-phase entry by diminishing Cyclin D1 dependent activities. Mol Cancer 2011; 10: 28.

    Article  CAS  Google Scholar 

  22. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, Egler RA et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009; 8: 2461–2469.

    Article  CAS  Google Scholar 

  23. Yang H, Ou CC, Feldman RI, Nicosia SV, Kruk PA, Cheng JQ . Aurora-A kinase regulates telomerase activity through c-Myc in human ovarian and breast epithelial cells. Cancer Res 2004; 64: 463–467.

    Article  CAS  Google Scholar 

  24. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM et al. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther 2010; 9: 1298–1307.

    Article  CAS  Google Scholar 

  25. Yao J, Yan M, Guan Z, Pan CB, Xia LP, Li CX et al. Aurora-A down-regulates I kappa B-á via Akt activation and interacts with insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer cell survival. Mol Cancer 2009; 8: 95.

    Article  Google Scholar 

  26. Yang H, He LL, Kruk P, Nicosia SV, Cheng JQ . Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 2006; 10: 2304–2312.

    Article  Google Scholar 

  27. Boss DS, Beijnen JH, Schellens JH . Clinical experience with Aurora kinase inhibitors: a review. Oncologist 2009; 14: 780–793.

    Article  CAS  Google Scholar 

  28. Ayuk MA, Suttiprapa S, Rinaldi G, Mann VH, Lee CM, Brindley PJ . Schistosoma mansoni U6 gene promoter-driven short hairpin RNA induces RNA interference in human fibrosarcoma cells and schistosomules. Int J Parasitol 2011; 41: 783–789.

    Article  CAS  Google Scholar 

  29. Nie L, Das TM, Wang Y, Su Q, Zhao Y, Feng Y . Regulation of U6 promoter activity by transcriptional interference in viral vector-based RNAi. Genomics Proteomics Bioinform 2010; 8: 170–179.

    Article  CAS  Google Scholar 

  30. Dyer V, Ely A, Bloom K, Weinberg M, Arbuthnot P . tRNA Lys3 promoter cassettes that efficiently express RNAi-activating antihepatitis B virus short hairpin RNAs. Biochem Biophys Res Commun 2010; 398: 640–646.

    Article  CAS  Google Scholar 

  31. Abrahamyan A, Nagy E, Golovan SP . Human H1 promoter expressed short hairpin RNAs (shRNAs) suppress avian influenza virus replication in chicken CH-SAH and canine MDCK cells. Antiviral Res 2009; 84: 159–167.

    Article  CAS  Google Scholar 

  32. Dong K, Wang R, Wang X, Shen JJ, Lin F, Gao P et al. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 2009; 113: 443–456.

    Article  CAS  Google Scholar 

  33. Wang R, Wei SH, Lin F, Wang X, Gao P, Dong K et al. Silencing Livin gene expression to inhibit proliferation and enhance chemosensitivity in tumor cells. Cancer Gene Ther 2008; 15: 402–412.

    Article  CAS  Google Scholar 

  34. Huang XF, Luo SK, Xu J, Li J, Xu DR, Wang LH et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008; 5: 2854–2865.

    Article  Google Scholar 

  35. Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP et al. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 2004; 279: 19643–19648.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank everyone of the department of Medicine Laboratory and Research Center in Tangdu Hospital, Fourth Military Medicine University for their sincere help and technical supports. This study was supported by grant from National Natural Science Foundation of China (no. 30772181).

Author information

Author notes

  1. M Long and G Yin: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Medicine Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xi’an, China

    M Long, L Liu, F Lin, X Wang, J Ren, J Wei, K Dong & H Zhang

  2. Department of Gynaecology and Obstetrics, Tangdu Hospital, Fourth Military Medical University, Xi’an, China

    G Yin

Authors
  1. M Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Zhang.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Long, M., Yin, G., Liu, L. et al. Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells. Cancer Gene Ther 19, 271–281 (2012). https://doi.org/10.1038/cgt.2011.89

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2011.89

Keywords

Search

Advanced search

Quick links